Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Zutphen – page 14

842 clinical trials in Zutphen, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Zutphen at a glance
842
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

842 trials in Zutphen

Open in trial search

Study of Janus kinase inhibitor dose reduction in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis who have achieved low disease activity

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Sint Maartenskliniek

Osteoarthritis

Recruiting

Study of intramuscular methylprednisolone acetate to treat pain in patients with hand osteoarthritis

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Sint Maartenskliniek

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:BeOne Medicines AG

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study of Atomoxetine to Reduce Freezing of Gait in Patients with Parkinson's Disease During OFF-State

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atomoxetine
  • Sponsor:Radboud universitair medisch centrum Stichting

Fungal infection+3

Recruiting

Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Amphotericin B
  • Sponsor:Basilea Pharmaceutica International AG Allschwil

Study to Evaluate IOpener-Melanoma Test for Predicting Response to Immunotherapy in Stage III or IV Skin Melanoma Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Pfizer Inc.

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Zutphen

What the registry says about research in the country

01 Respiratory Diseases

Clinical research focusing on respiratory conditions including innovative treatments for asthma and viral infections. Studies encompass evaluation of new vaccine combinations and safety assessments of inhalation devices.

  • RSV and COVID-19 vaccine co-administration
  • Moderate to severe asthma treatments
  • Chronic Obstructive Pulmonary Disease management
  • Bronchiectasis therapy

Investigations include both preventive measures and therapeutic interventions for respiratory conditions.

02 Cardiovascular Studies

Comprehensive research into cardiovascular health, examining treatments for various heart conditions and prevention of major cardiac events.

  • Atherosclerotic Cardiovascular Disease
  • Heart Failure Management
  • Post-Heart Attack Treatment
  • Acute Coronary Syndrome

Focus on innovative therapies and interventions to improve patient outcomes in heart-related conditions.

03 Oncology Research

Advanced studies in lung cancer treatment and innovative therapeutic approaches for various cancer types.

  • Non-Small Cell Lung Cancer therapies
  • Immunotherapy optimization
  • Mantle Cell Lymphoma treatment

Evaluating novel treatment combinations and immunotherapy approaches for better patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.